whitepaper
Product hub: Targeted protein degradation – next-generation therapeutics
Helen Harrison, Director of Screening at Amphista Therapeutics, discusses targeted protein degradation (TPD) and the discovery of drugs in this area.
List view / Grid view
Omics
article
Advancing vaccines with extracellular vesicles
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
article
Building a powerful portfolio of sepsis biomarker signatures for therapeutic clinical trials
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
article
Synthetic biology is ready for the therapeutic limelight
After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
article
Advancing novel biotherapeutics based on synthetic biology
Researchers at Synlogic are clearing the path for a new class of medicine – biotherapeutics based on synthetic biology, called synthetic biotics, which are created by programming or engineering bacteria to metabolise or secrete well-validated targets of disease pathophysiology. In this article, Dr Caroline Kurtz, Chief Development Officer at Synlogic, discusses how synthetic…
article
Drug Target Review Synthetic Biology ebook 2022
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
news
Researchers develop NPHP5 gene therapy for rare ciliopathy
The researchers found that augmenting NPHP5 gene rescues cilia defects in light-sensing cells derived from ciliopathy patients.
article
T-cell redirecting bispecific antibodies: the next era of immune-based therapies for multiple myeloma?
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
article
Next-generation CRISPR technologies for treating human diseases
Genome editing technologies could accelerate the translation of genetic advances into new therapeutics. Here, Dr Pushpanathan Muthuirulan, Research Associate at Harvard University, explores the potential of CRISPR to treat and cure genetic conditions.
article
Drug Target Review Neuroscience ebook 2022
This ebook includes articles on the latest Alzheimer's research on how to potentially target tau and also how new human disease models can enable the development of transformational novel therapeutics.
article
Drug Target Review Assays ebook 2022
Included in this ebook are pieces on how an assay for the detection of sepsis was developed and a new high-throughput assay that could reveal new drugs to fight COVID-19.
article
Drug Target Review Antibodies ebook 2022
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
article
Drug Target Review – Issue 3 2022
In this issue are articles on synthetically engineered bacteria to deliver therapeutics, how single-molecule fluorescence resonance energy transfer was used to image GPCRs and a new assay to identify coronavirus drugs. Also included are pieces on vaccine development, monoclonal antibodies and neuroscience.
podcasts
Episode 12 – ELISA assays with Dr Ana Miletic and Anna Dey, Kyowa Kirin & Dr Cathy Olsen, Molecular Devices
In this episode, experts discuss how they use ELISA assays in their research as well as the specific benefits of this kind of immunoassay.
